Equities analysts forecast that CONMED Co. (NASDAQ:CNMD – Get Rating) will announce earnings per share of $0.62 for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for CONMED’s earnings. The highest EPS estimate is $0.65 and the lowest is $0.55. CONMED posted earnings per share of $0.63 in the same quarter last year, which suggests a negative year-over-year growth rate of 1.6%. The company is expected to announce its next earnings results after the market closes on Monday, January 1st.
On average, analysts expect that CONMED will report full-year earnings of $3.70 per share for the current financial year, with EPS estimates ranging from $3.67 to $3.73. For the next year, analysts expect that the business will report earnings of $4.27 per share, with EPS estimates ranging from $4.22 to $4.30. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for CONMED.
Separately, StockNews.com started coverage on CONMED in a research note on Thursday, March 31st. They set a “hold” rating on the stock.
CONMED Company Profile (Get Rating)
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.
- Get a free copy of the StockNews.com research report on CONMED (CNMD)
- NextEra Energy Offers a Long-Term Gain if You Can Tolerate Short-Term Pain
- Steel Dynamics Scales New Heights On Record Results
- The Institutions Are Driving Knight-Swift Transportation
- Tesla (NASDAQ: TSLA) Stock Hits Four Figures Once Again
- 3 Legendary Low-Beta Stocks Set to Outperform
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.